Company: ABBV
Filing Date: 2025-03-24
Form Type: DEF 14A
Source: 0001558370-25-003537
Chunk: 33

Company: AbbVie Inc.
Filing Date: 2025-03-24
Form: DEF 14A
Chunk 33
---
). The Platform Revenue target and result are adjusted for foreign exchange because it is unpredictable at the time the target is set. |

| (3) | Evaluated on a constant currency basis. |

42 | 2025 Proxy Statement

| ​ | ​                      |
| ​ | EXECUTIVE COMPENSATION |

Short-Term Incentive Strategic and Leadership Goals Each NEO achieved or exceeded their 2024 strategic and leadership goals, which are listed below:

| ● | Robert A. Michael: Execute key strategic initiatives to drive sustainable long-term business performance; deliver value to our stockholders; build investor confidence and credibility; successfully advance mid- and late-stage pipeline assets; continue to drive employee engagement and motivation around AbbVie’s mission and future prospects; advance our transformation to a biopharmaceutical culture; and achieve proprietary pharmaceutical pipeline enhancement objectives. |

| ● | Richard A. Gonzalez: Execute key strategic initiatives to drive sustainable long-term business performance; successfully advance mid- and late-stage pipeline assets; maintain shareholder value through investor activities; and support a successful CEO transition through expert advice and mentorship to Mr. Michael as he transitions to lead the company. |

| ● | Scott T. Reents: Drive enterprise finance strategic initiatives and transformation on key financial processes; ensure execution and provide oversight of company financial goals; and achieve transaction integration objectives. |

| ● | Jeffrey R. Stewart: Achieve key product milestones; drive patient access for all therapies across the different franchises; and successfully adapt and execute market strategies relative to external considerations. |

| ● | Azita Saleki-Gerhardt: Successfully drive operations optimization and milestones; execute on objectives including product launches and financial goals; and support research and development initiatives per company strategy. |

| ● | Timothy J. Richmond: Elevate and build AbbVie’s culture aligned with organizational objectives; drive core HR capabilities focusing on employee experience and leadership development; and lead relevant efforts linked to company strategy that enhance AbbVie’s reputation, promote effective governance, ensure the future sustainability of our business and provide robust talent sources. |

Assessments of performance against financial results consider the effect of foreign exchange and other specified adjustments and/or unusual or unpredictable events, and the appropriateness of these adjustments is reviewed annually by the committee. In 2024, specified adjustments included intangible asset amortization, acquisition and integration-related costs, IPR&D and milestones expense, change in fair value of contingent consideration, impacts related to the settlement of income tax examinations and changes in income tax reserves, and other items,